購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
huPD-1 Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huPD-1 Mouse
製品名
huPD-1 Mouse
製品ID
C001524
系統名
C57BL/6JCya-Pdcd1em1(hPDCD1)/Cya
背景情報
C57BL/6JCya
状況
このマウス系統を論文で使用する場合は、「huPD-1 Mouse(カタログ番号C001524)はサイアジェンから購入しました。」と引用してください。
HUGO-GT Humanized Models
Tumor Target Humanized Mouse Models
Immune Target Humanized Mouse Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
HUGO-GT Humanized Models
Tumor Target Humanized Mouse Models
Immune Target Humanized Mouse Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
PD1, PD-1, CD279, SLEB2, hPD-1, hPD-l, hSLE1
NCBI ID
染色体
Chr 2
MGI ID
さらに
系統詳細
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 costimulatory receptor family. It is an inhibitory receptor expressed on activated T cells and plays a role in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in a variety of tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in the defense against autoimmune diseases and has inhibitory effects on antitumor and antimicrobial immunity [1]. PD-1 binds to programmed death ligands 1 and 2 (PD-L1 and PD-L2) to inhibit T cell activation, reduce the production of corresponding cytokines, and regulate T cell survival [2]. Drugs targeting this pathway can reactivate T cells to activate antitumor immune responses [3].
This strain is a genetically modified mouse model in which the gene encoding the mouse PD-1 protein is humanized, resulting in the expression of human PD-1 protein in mice. This model can be used for research in drug development, efficacy and safety evaluation, tumor immunotherapy evaluation, and immune system mechanisms related to PD-1.
参考文献
National Center for Biotechnology Information. "Gene: PDCD1." NCBI, U.S. National Library of Medicine, 2023, www.ncbi.nlm.nih.gov/gene/5133
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007 Jul;19(7):813-24.
Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018 Mar;18(3):153-167.
Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016 Nov;12(11):2777-2789.
系統作製戦略
The mouse Pdcd1 gene was edited using gene editing technology to replace the sequence encoding the extracellular domain of mouse PD-1 protein with the sequence from the human PD1 gene encoding the human PD-1 protein extracellular domain while retaining the mouse signal peptide.

Figure 1. Gene editing strategy for huPD-1 mice.
適用分野
Development and screening of PD-1-targeted drugs;
Efficacy and safety evaluation of PD-1-targeted drugs;
Evaluation of tumor immunotherapy;
Research on the immune system and tumor immune escape mechanisms.
検証 Data
1. Detection of Human PD1 Protein Expression in the Spleen
The results show that there is significant expression of human PD1 protein in the splenic cells of hPD1 mice 72 hours post-activation.

Figure 2. Detection of human PD1 (hCD279) expression after ex vivo activation of splenic cells.
2. In vivo efficacy of anti-human PD-1 antibody
The colon adenocarcinoma model was established in female huPD-1 mice (6 weeks old, n=5) via subcutaneous injection of the MC38 cells. Mice in the treatment group received the anti-human PD-1 antibody, Pembrolizumab, biweekly (BIW) [4]. During the experimental period, measurements of tumor volume and mouse weight were taken twice weekly, and at the end of the experiment, the mouse tumor tissue was removed for tumor weight measurement. The results showed that MC38 cells can form tumors in huPD-1 mice, and Pembrolizumab treatment can effectively inhibit tumor growth (Figure 3.a-b). While all mice exhibited a progressive increase in weight, a notable weight discrepancy was observed between the treatment and non-treatment groups (Figure 3.c).

Figure 3. Evaluation of the Antitumor Activity of the Anti-human PD-1 Antibody in huPD-1 Mice.
関連リソース
お問い合わせ
ご不明な点やご質問などございましたら、お気軽にお問い合わせください。担当スタッフがサポートさせていただきます。下記のフォームにご記入いただければ、1〜2営業日以内に折り返しご連絡いたします。
Related Product
All Related ProductsResources
Publications
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
